文献速递小儿眼科与斜弱视角膜与眼表疾病

幼年特发性关节炎相关葡萄膜炎患儿局部糖皮质激素治疗的白内障风险

Risk of Cataract Development among Children with Juvenile Idiopathic Arthritis-Related Uveitis Treated with Topical Corticosteroids.
PubMed 文献 · Ophthalmology · 2020-01-01

回顾性队列研究纳入75例幼年特发性关节炎相关葡萄膜炎患者,中位随访4年,新发白内障发生率为0.04/眼年(95%CI 0.02-0.09)。局部糖皮质激素使用呈剂量依赖性增加白内障风险,每日超过3滴组发生率0.16/眼年,而每日少于3滴组为0.01/眼年(P=0.0006)。

要点

  • 局部糖皮质激素每日超过3滴时白内障发生率显著升高。
  • 每日少于2滴组白内障发生率为0/眼年,提示低剂量可能更安全。
  • 后粘连、活动性葡萄膜炎和就诊时使用局部糖皮质激素与白内障发展显著相关。

核心结论

  • 局部糖皮质激素使用与白内障形成风险增加相关,独立于活动性葡萄膜炎或后粘连存在。
  • 在葡萄膜炎控制的情况下,长期每日少于3滴的局部糖皮质激素似乎与较低的白内障发展风险相关。

研究设计与样本

  • 回顾性队列研究,纳入1984年7月至2005年8月单中心观察的75例幼年特发性关节炎相关葡萄膜炎患者。
  • 通过病历回顾收集临床数据并分析,主要结局为新发白内障发生率。

主要发现

  • 中位随访4年,新发白内障发生率为0.04/眼年(95%CI 0.02-0.09)。
  • 40例患者共60眼接受局部糖皮质激素治疗,白内障发生率呈剂量依赖性增加。
  • 每日少于3滴组白内障发生率为0.01/眼年,每日超过3滴组为0.16/眼年(log-rank检验P=0.0006)。
  • 每日少于2滴组白内障发生率为0/眼年(单侧95%CI 0.03/眼年)。
  • 后粘连、活动性葡萄膜炎和就诊时使用局部糖皮质激素与白内障发展显著相关。

关键数值与推荐

  • 每日超过3滴局部糖皮质激素组白内障发生率为0.16/眼年,每日少于3滴组为0.01/眼年。
  • 纵向数据分析显示,在控制葡萄膜炎持续时间、活动性葡萄膜炎的存在和程度以及时间更新的其他糖皮质激素使用后,每日少于3滴治疗与每日超过3滴相比,白内障形成风险降低87%(相对风险0.13;95%CI 0.02-0.69;P=0.02)。

临床怎么用

  • 对幼年特发性关节炎相关葡萄膜炎患儿使用局部糖皮质激素时,应关注剂量与白内障风险的关系。
  • 在葡萄膜炎控制的情况下,考虑将局部糖皮质激素剂量维持在每日少于3滴以降低白内障风险。

局限性

  • 单中心回顾性队列研究,样本量75例,可能存在选择偏倚和信息偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We sought to investigate the risk of cataract development among patients with juvenile idiopathic arthritis (JIA)-associated uveitis treated with topical corticosteroids. DESIGN: Retrospective cohort study. PARTICIPANTS: We included 75 patients with JIA-associated uveitis observed from July 1984 through August 2005 at a single academic center. METHODS: Clinical data on these patients were collected by chart review and were analyzed. MAIN OUTCOME MEASURES: Incidence of new-onset cataract. Risk factors for cataract development were assessed with attention paid to the use of topical corticosteroids. RESULTS: Over a median follow-up of 4 years, the incidence of new-onset cataract was 0.04/eye-year (EY; 95% confidence interval [CI], 0.02-0.09). Of the 60 eyes in 40 patients who received topical corticosteroid therapy, there was a dose-dependent increase in the rate of cataract development among eyes receiving topical corticosteroids. The incidence of cataract was 0.01/EY for eyes treated with <3 drops daily and 0.16/EY (P = 0.0006 for log-rank test) for eyes treated with >3 drops daily. Among eyes receiving <2 drops daily, the incidence of cataract was 0/EY (95% CI [1 sided], 0.03/EY). Presence of posterior synechiae, active uveitis, and use of topical corticosteroids at presentation were significantly associated with cataract development after controlling for confounding variables. Use of topical corticosteroids was associated with cataract formation independent of uveitis activity. Using longitudinal data analysis and controlling for duration of uveitis, presence and degree of active uveitis, and concomitant use of other forms of corticosteroids in a time-updated fashion, treatment with <3 drops daily of topical corticosteroid was associated with an 87% lower risk of cataract formation compared with eyes treated with >3 drops daily (relative risk, 0.13; 95% CI, 0.02-0.69; P = 0.02). CONCLUSIONS: In our cohort, topical corticosteroid use was associated with an increased risk of cataract formation independent of active uveitis or presence of posterior synechiae. However, chronic use of topical corticosteroids dosed at <3 drops daily seemed to be associated with a lower risk of cataract development relative to eyes receiving higher doses over follow-up in the setting of suppressed uveitis. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Thorne JE, Woreta FA, Dunn JP, et al. Risk of Cataract Development among Children with Juvenile Idiopathic Arthritis-Related Uveitis Treated with Topical Corticosteroids. Ophthalmology. 2020. PMID: 32200821. doi:10.1016/j.ophtha.2020.01.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。